nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—CYP2D6—Temsirolimus—kidney cancer	0.133	0.372	CbGbCtD
Dextroamphetamine—CYP2D6—Pazopanib—kidney cancer	0.0698	0.195	CbGbCtD
Dextroamphetamine—CYP2D6—Erlotinib—kidney cancer	0.0498	0.139	CbGbCtD
Dextroamphetamine—CYP2D6—Sorafenib—kidney cancer	0.0405	0.113	CbGbCtD
Dextroamphetamine—CYP2D6—Vinblastine—kidney cancer	0.04	0.112	CbGbCtD
Dextroamphetamine—CYP2D6—Doxorubicin—kidney cancer	0.0246	0.0687	CbGbCtD
Dextroamphetamine—Pseudoephedrine—IL2—kidney cancer	0.0031	0.25	CrCbGaD
Dextroamphetamine—Ephedrine—ACHE—kidney cancer	0.00242	0.195	CrCbGaD
Dextroamphetamine—Lacosamide—CA9—kidney cancer	0.00182	0.147	CrCbGaD
Dextroamphetamine—Lacosamide—CA2—kidney cancer	0.00164	0.132	CrCbGaD
Dextroamphetamine—Ephedrine—BCHE—kidney cancer	0.00142	0.115	CrCbGaD
Dextroamphetamine—Agitation—Vincristine—kidney cancer	0.000988	0.00178	CcSEcCtD
Dextroamphetamine—Abdominal pain—Vinblastine—kidney cancer	0.000986	0.00177	CcSEcCtD
Dextroamphetamine—Headache—Pazopanib—kidney cancer	0.000986	0.00177	CcSEcCtD
Dextroamphetamine—Abdominal pain—Everolimus—kidney cancer	0.000982	0.00177	CcSEcCtD
Dextroamphetamine—Body temperature increased—Everolimus—kidney cancer	0.000982	0.00177	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Erlotinib—kidney cancer	0.00098	0.00176	CcSEcCtD
Dextroamphetamine—Infection—Dactinomycin—kidney cancer	0.000976	0.00176	CcSEcCtD
Dextroamphetamine—Dyspnoea—Sorafenib—kidney cancer	0.000961	0.00173	CcSEcCtD
Dextroamphetamine—Dyspepsia—Sorafenib—kidney cancer	0.000949	0.00171	CcSEcCtD
Dextroamphetamine—Abdominal pain—Erlotinib—kidney cancer	0.000948	0.00171	CcSEcCtD
Dextroamphetamine—Body temperature increased—Erlotinib—kidney cancer	0.000948	0.00171	CcSEcCtD
Dextroamphetamine—Insomnia—Sunitinib—kidney cancer	0.000939	0.00169	CcSEcCtD
Dextroamphetamine—Decreased appetite—Sorafenib—kidney cancer	0.000937	0.00169	CcSEcCtD
Dextroamphetamine—Anorexia—Dactinomycin—kidney cancer	0.000936	0.00168	CcSEcCtD
Dextroamphetamine—Nausea—Pazopanib—kidney cancer	0.000935	0.00168	CcSEcCtD
Dextroamphetamine—Convulsion—Vincristine—kidney cancer	0.000932	0.00168	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000931	0.00168	CcSEcCtD
Dextroamphetamine—Fatigue—Sorafenib—kidney cancer	0.00093	0.00167	CcSEcCtD
Dextroamphetamine—Hypertension—Vincristine—kidney cancer	0.000929	0.00167	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Paclitaxel—kidney cancer	0.000928	0.00167	CcSEcCtD
Dextroamphetamine—Dyspnoea—Sunitinib—kidney cancer	0.000925	0.00166	CcSEcCtD
Dextroamphetamine—Constipation—Sorafenib—kidney cancer	0.000922	0.00166	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Vinblastine—kidney cancer	0.000919	0.00165	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Capecitabine—kidney cancer	0.000918	0.00165	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Everolimus—kidney cancer	0.000915	0.00165	CcSEcCtD
Dextroamphetamine—Dyspepsia—Sunitinib—kidney cancer	0.000913	0.00164	CcSEcCtD
Dextroamphetamine—Weight decreased—Capecitabine—kidney cancer	0.00091	0.00164	CcSEcCtD
Dextroamphetamine—Decreased appetite—Sunitinib—kidney cancer	0.000902	0.00162	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000896	0.00161	CcSEcCtD
Dextroamphetamine—Asthenia—Vinblastine—kidney cancer	0.000895	0.00161	CcSEcCtD
Dextroamphetamine—Fatigue—Sunitinib—kidney cancer	0.000895	0.00161	CcSEcCtD
Dextroamphetamine—Depression—Capecitabine—kidney cancer	0.000894	0.00161	CcSEcCtD
Dextroamphetamine—Asthenia—Everolimus—kidney cancer	0.000891	0.0016	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.000889	0.0016	CcSEcCtD
Dextroamphetamine—Constipation—Sunitinib—kidney cancer	0.000887	0.0016	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Capecitabine—kidney cancer	0.000884	0.00159	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Sorafenib—kidney cancer	0.000882	0.00159	CcSEcCtD
Dextroamphetamine—Hypertension—Gemcitabine—kidney cancer	0.000881	0.00158	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Capecitabine—kidney cancer	0.000879	0.00158	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Vincristine—kidney cancer	0.000878	0.00158	CcSEcCtD
Dextroamphetamine—Infection—Vincristine—kidney cancer	0.000872	0.00157	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Capecitabine—kidney cancer	0.000872	0.00157	CcSEcCtD
Dextroamphetamine—Chest pain—Gemcitabine—kidney cancer	0.000869	0.00156	CcSEcCtD
Dextroamphetamine—Asthenia—Erlotinib—kidney cancer	0.00086	0.00155	CcSEcCtD
Dextroamphetamine—Urticaria—Sorafenib—kidney cancer	0.000857	0.00154	CcSEcCtD
Dextroamphetamine—Decreased appetite—Dactinomycin—kidney cancer	0.000854	0.00154	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vinblastine—kidney cancer	0.000853	0.00154	CcSEcCtD
Dextroamphetamine—Body temperature increased—Sorafenib—kidney cancer	0.000853	0.00153	CcSEcCtD
Dextroamphetamine—Abdominal pain—Sorafenib—kidney cancer	0.000853	0.00153	CcSEcCtD
Dextroamphetamine—Diarrhoea—Everolimus—kidney cancer	0.00085	0.00153	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Sunitinib—kidney cancer	0.000849	0.00153	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Vincristine—kidney cancer	0.000849	0.00153	CcSEcCtD
Dextroamphetamine—Fatigue—Dactinomycin—kidney cancer	0.000847	0.00152	CcSEcCtD
Dextroamphetamine—Tension—Paclitaxel—kidney cancer	0.000838	0.00151	CcSEcCtD
Dextroamphetamine—Anorexia—Vincristine—kidney cancer	0.000837	0.00151	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000833	0.0015	CcSEcCtD
Dextroamphetamine—Nervousness—Paclitaxel—kidney cancer	0.00083	0.00149	CcSEcCtD
Dextroamphetamine—Infection—Gemcitabine—kidney cancer	0.000827	0.00149	CcSEcCtD
Dextroamphetamine—Dizziness—Vinblastine—kidney cancer	0.000825	0.00148	CcSEcCtD
Dextroamphetamine—Dizziness—Everolimus—kidney cancer	0.000822	0.00148	CcSEcCtD
Dextroamphetamine—Body temperature increased—Sunitinib—kidney cancer	0.00082	0.00148	CcSEcCtD
Dextroamphetamine—Abdominal pain—Sunitinib—kidney cancer	0.00082	0.00148	CcSEcCtD
Dextroamphetamine—Diarrhoea—Erlotinib—kidney cancer	0.00082	0.00148	CcSEcCtD
Dextroamphetamine—Benzyl alcohol—CYP1A1—kidney cancer	0.000809	0.0653	CrCbGaD
Dextroamphetamine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000805	0.00145	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000803	0.00145	CcSEcCtD
Dextroamphetamine—Tremor—Paclitaxel—kidney cancer	0.0008	0.00144	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Sorafenib—kidney cancer	0.000795	0.00143	CcSEcCtD
Dextroamphetamine—Insomnia—Vincristine—kidney cancer	0.000794	0.00143	CcSEcCtD
Dextroamphetamine—Anorexia—Gemcitabine—kidney cancer	0.000794	0.00143	CcSEcCtD
Dextroamphetamine—Vomiting—Vinblastine—kidney cancer	0.000793	0.00143	CcSEcCtD
Dextroamphetamine—Dizziness—Erlotinib—kidney cancer	0.000793	0.00143	CcSEcCtD
Dextroamphetamine—Vomiting—Everolimus—kidney cancer	0.00079	0.00142	CcSEcCtD
Dextroamphetamine—Agitation—Paclitaxel—kidney cancer	0.000785	0.00141	CcSEcCtD
Dextroamphetamine—Rash—Everolimus—kidney cancer	0.000783	0.00141	CcSEcCtD
Dextroamphetamine—Dermatitis—Everolimus—kidney cancer	0.000783	0.00141	CcSEcCtD
Dextroamphetamine—Headache—Vinblastine—kidney cancer	0.000781	0.00141	CcSEcCtD
Dextroamphetamine—Angioedema—Paclitaxel—kidney cancer	0.000781	0.0014	CcSEcCtD
Dextroamphetamine—Headache—Everolimus—kidney cancer	0.000778	0.0014	CcSEcCtD
Dextroamphetamine—Abdominal pain—Dactinomycin—kidney cancer	0.000777	0.0014	CcSEcCtD
Dextroamphetamine—Body temperature increased—Dactinomycin—kidney cancer	0.000777	0.0014	CcSEcCtD
Dextroamphetamine—Asthenia—Sorafenib—kidney cancer	0.000774	0.00139	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.000766	0.00138	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Sunitinib—kidney cancer	0.000765	0.00138	CcSEcCtD
Dextroamphetamine—Decreased appetite—Vincristine—kidney cancer	0.000763	0.00137	CcSEcCtD
Dextroamphetamine—Vomiting—Erlotinib—kidney cancer	0.000762	0.00137	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Capecitabine—kidney cancer	0.000761	0.00137	CcSEcCtD
Dextroamphetamine—Nateglinide—PTGS1—kidney cancer	0.000759	0.0612	CrCbGaD
Dextroamphetamine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000758	0.00136	CcSEcCtD
Dextroamphetamine—Fatigue—Vincristine—kidney cancer	0.000757	0.00136	CcSEcCtD
Dextroamphetamine—Rash—Erlotinib—kidney cancer	0.000756	0.00136	CcSEcCtD
Dextroamphetamine—Dermatitis—Erlotinib—kidney cancer	0.000755	0.00136	CcSEcCtD
Dextroamphetamine—Palpitations—Paclitaxel—kidney cancer	0.000755	0.00136	CcSEcCtD
Dextroamphetamine—Insomnia—Gemcitabine—kidney cancer	0.000753	0.00136	CcSEcCtD
Dextroamphetamine—Headache—Erlotinib—kidney cancer	0.000751	0.00135	CcSEcCtD
Dextroamphetamine—Constipation—Vincristine—kidney cancer	0.000751	0.00135	CcSEcCtD
Dextroamphetamine—Asthenia—Sunitinib—kidney cancer	0.000745	0.00134	CcSEcCtD
Dextroamphetamine—Dyspnoea—Gemcitabine—kidney cancer	0.000742	0.00134	CcSEcCtD
Dextroamphetamine—Nausea—Vinblastine—kidney cancer	0.000741	0.00133	CcSEcCtD
Dextroamphetamine—Somnolence—Gemcitabine—kidney cancer	0.00074	0.00133	CcSEcCtD
Dextroamphetamine—Convulsion—Paclitaxel—kidney cancer	0.00074	0.00133	CcSEcCtD
Dextroamphetamine—Affect lability—Doxorubicin—kidney cancer	0.000739	0.00133	CcSEcCtD
Dextroamphetamine—Nausea—Everolimus—kidney cancer	0.000738	0.00133	CcSEcCtD
Dextroamphetamine—Diarrhoea—Sorafenib—kidney cancer	0.000738	0.00133	CcSEcCtD
Dextroamphetamine—Hypertension—Paclitaxel—kidney cancer	0.000737	0.00133	CcSEcCtD
Dextroamphetamine—Chest pain—Paclitaxel—kidney cancer	0.000727	0.00131	CcSEcCtD
Dextroamphetamine—Anxiety—Paclitaxel—kidney cancer	0.000725	0.0013	CcSEcCtD
Dextroamphetamine—Decreased appetite—Gemcitabine—kidney cancer	0.000724	0.0013	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Dactinomycin—kidney cancer	0.000724	0.0013	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000719	0.00129	CcSEcCtD
Dextroamphetamine—Fatigue—Gemcitabine—kidney cancer	0.000718	0.00129	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Vincristine—kidney cancer	0.000718	0.00129	CcSEcCtD
Dextroamphetamine—Dizziness—Sorafenib—kidney cancer	0.000713	0.00128	CcSEcCtD
Dextroamphetamine—Constipation—Gemcitabine—kidney cancer	0.000712	0.00128	CcSEcCtD
Dextroamphetamine—Nausea—Erlotinib—kidney cancer	0.000712	0.00128	CcSEcCtD
Dextroamphetamine—Dry mouth—Paclitaxel—kidney cancer	0.000711	0.00128	CcSEcCtD
Dextroamphetamine—Mood swings—Doxorubicin—kidney cancer	0.000711	0.00128	CcSEcCtD
Dextroamphetamine—Diarrhoea—Sunitinib—kidney cancer	0.00071	0.00128	CcSEcCtD
Dextroamphetamine—Asthenia—Dactinomycin—kidney cancer	0.000705	0.00127	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000697	0.00125	CcSEcCtD
Dextroamphetamine—Abdominal pain—Vincristine—kidney cancer	0.000694	0.00125	CcSEcCtD
Dextroamphetamine—Body temperature increased—Vincristine—kidney cancer	0.000694	0.00125	CcSEcCtD
Dextroamphetamine—Infection—Paclitaxel—kidney cancer	0.000693	0.00125	CcSEcCtD
Dextroamphetamine—Dizziness—Sunitinib—kidney cancer	0.000686	0.00123	CcSEcCtD
Dextroamphetamine—Vomiting—Sorafenib—kidney cancer	0.000686	0.00123	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Doxorubicin—kidney cancer	0.000685	0.00123	CcSEcCtD
Dextroamphetamine—Tachycardia—Paclitaxel—kidney cancer	0.00068	0.00122	CcSEcCtD
Dextroamphetamine—Rash—Sorafenib—kidney cancer	0.00068	0.00122	CcSEcCtD
Dextroamphetamine—Dermatitis—Sorafenib—kidney cancer	0.000679	0.00122	CcSEcCtD
Dextroamphetamine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.000676	0.00122	CcSEcCtD
Dextroamphetamine—Headache—Sorafenib—kidney cancer	0.000676	0.00122	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Paclitaxel—kidney cancer	0.000674	0.00121	CcSEcCtD
Dextroamphetamine—Diarrhoea—Dactinomycin—kidney cancer	0.000672	0.00121	CcSEcCtD
Dextroamphetamine—Anorexia—Paclitaxel—kidney cancer	0.000665	0.0012	CcSEcCtD
Dextroamphetamine—Vomiting—Sunitinib—kidney cancer	0.00066	0.00119	CcSEcCtD
Dextroamphetamine—Body temperature increased—Gemcitabine—kidney cancer	0.000658	0.00118	CcSEcCtD
Dextroamphetamine—Tremor—Capecitabine—kidney cancer	0.000657	0.00118	CcSEcCtD
Dextroamphetamine—Rash—Sunitinib—kidney cancer	0.000654	0.00118	CcSEcCtD
Dextroamphetamine—Dermatitis—Sunitinib—kidney cancer	0.000654	0.00118	CcSEcCtD
Dextroamphetamine—Headache—Sunitinib—kidney cancer	0.00065	0.00117	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Vincristine—kidney cancer	0.000647	0.00116	CcSEcCtD
Dextroamphetamine—Nausea—Sorafenib—kidney cancer	0.000641	0.00115	CcSEcCtD
Dextroamphetamine—Insomnia—Paclitaxel—kidney cancer	0.000631	0.00113	CcSEcCtD
Dextroamphetamine—Asthenia—Vincristine—kidney cancer	0.00063	0.00113	CcSEcCtD
Dextroamphetamine—Vomiting—Dactinomycin—kidney cancer	0.000625	0.00112	CcSEcCtD
Dextroamphetamine—Dyspnoea—Paclitaxel—kidney cancer	0.000622	0.00112	CcSEcCtD
Dextroamphetamine—Somnolence—Paclitaxel—kidney cancer	0.00062	0.00112	CcSEcCtD
Dextroamphetamine—Palpitations—Capecitabine—kidney cancer	0.000619	0.00111	CcSEcCtD
Dextroamphetamine—Rash—Dactinomycin—kidney cancer	0.000619	0.00111	CcSEcCtD
Dextroamphetamine—Nausea—Sunitinib—kidney cancer	0.000616	0.00111	CcSEcCtD
Dextroamphetamine—Dyspepsia—Paclitaxel—kidney cancer	0.000614	0.0011	CcSEcCtD
Dextroamphetamine—Decreased appetite—Paclitaxel—kidney cancer	0.000606	0.00109	CcSEcCtD
Dextroamphetamine—Hypertension—Capecitabine—kidney cancer	0.000605	0.00109	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000602	0.00108	CcSEcCtD
Dextroamphetamine—Fatigue—Paclitaxel—kidney cancer	0.000601	0.00108	CcSEcCtD
Dextroamphetamine—Diarrhoea—Vincristine—kidney cancer	0.000601	0.00108	CcSEcCtD
Dextroamphetamine—Asthenia—Gemcitabine—kidney cancer	0.000597	0.00107	CcSEcCtD
Dextroamphetamine—Chest pain—Capecitabine—kidney cancer	0.000597	0.00107	CcSEcCtD
Dextroamphetamine—Constipation—Paclitaxel—kidney cancer	0.000596	0.00107	CcSEcCtD
Dextroamphetamine—Anxiety—Capecitabine—kidney cancer	0.000595	0.00107	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000592	0.00107	CcSEcCtD
Dextroamphetamine—Weight decreased—Doxorubicin—kidney cancer	0.000587	0.00106	CcSEcCtD
Dextroamphetamine—Dry mouth—Capecitabine—kidney cancer	0.000584	0.00105	CcSEcCtD
Dextroamphetamine—Nausea—Dactinomycin—kidney cancer	0.000584	0.00105	CcSEcCtD
Dextroamphetamine—Dizziness—Vincristine—kidney cancer	0.00058	0.00104	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000573	0.00103	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Paclitaxel—kidney cancer	0.00057	0.00103	CcSEcCtD
Dextroamphetamine—Diarrhoea—Gemcitabine—kidney cancer	0.00057	0.00103	CcSEcCtD
Dextroamphetamine—Infection—Capecitabine—kidney cancer	0.000568	0.00102	CcSEcCtD
Dextroamphetamine—Urinary tract infection—Doxorubicin—kidney cancer	0.000562	0.00101	CcSEcCtD
Dextroamphetamine—Tachycardia—Capecitabine—kidney cancer	0.000558	0.001	CcSEcCtD
Dextroamphetamine—Vomiting—Vincristine—kidney cancer	0.000558	0.001	CcSEcCtD
Dextroamphetamine—Sweating—Doxorubicin—kidney cancer	0.000554	0.000997	CcSEcCtD
Dextroamphetamine—Urticaria—Paclitaxel—kidney cancer	0.000554	0.000997	CcSEcCtD
Dextroamphetamine—Rash—Vincristine—kidney cancer	0.000553	0.000996	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Capecitabine—kidney cancer	0.000553	0.000995	CcSEcCtD
Dextroamphetamine—Dermatitis—Vincristine—kidney cancer	0.000553	0.000995	CcSEcCtD
Dextroamphetamine—Abdominal pain—Paclitaxel—kidney cancer	0.000551	0.000992	CcSEcCtD
Dextroamphetamine—Body temperature increased—Paclitaxel—kidney cancer	0.000551	0.000992	CcSEcCtD
Dextroamphetamine—Headache—Vincristine—kidney cancer	0.00055	0.000989	CcSEcCtD
Dextroamphetamine—Anorexia—Capecitabine—kidney cancer	0.000545	0.000981	CcSEcCtD
Dextroamphetamine—Vomiting—Gemcitabine—kidney cancer	0.000529	0.000953	CcSEcCtD
Dextroamphetamine—Rash—Gemcitabine—kidney cancer	0.000525	0.000945	CcSEcCtD
Dextroamphetamine—Dermatitis—Gemcitabine—kidney cancer	0.000525	0.000944	CcSEcCtD
Dextroamphetamine—Headache—Gemcitabine—kidney cancer	0.000522	0.000939	CcSEcCtD
Dextroamphetamine—Nausea—Vincristine—kidney cancer	0.000521	0.000938	CcSEcCtD
Dextroamphetamine—Insomnia—Capecitabine—kidney cancer	0.000517	0.000931	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Paclitaxel—kidney cancer	0.000514	0.000924	CcSEcCtD
Dextroamphetamine—Dyspnoea—Capecitabine—kidney cancer	0.00051	0.000918	CcSEcCtD
Dextroamphetamine—Dyspepsia—Capecitabine—kidney cancer	0.000504	0.000906	CcSEcCtD
Dextroamphetamine—Asthenia—Paclitaxel—kidney cancer	0.0005	0.0009	CcSEcCtD
Dextroamphetamine—Decreased appetite—Capecitabine—kidney cancer	0.000497	0.000895	CcSEcCtD
Dextroamphetamine—Nausea—Gemcitabine—kidney cancer	0.000495	0.00089	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000494	0.000889	CcSEcCtD
Dextroamphetamine—Fatigue—Capecitabine—kidney cancer	0.000493	0.000887	CcSEcCtD
Dextroamphetamine—Erythema multiforme—Doxorubicin—kidney cancer	0.000491	0.000883	CcSEcCtD
Dextroamphetamine—Constipation—Capecitabine—kidney cancer	0.000489	0.00088	CcSEcCtD
Dextroamphetamine—Diarrhoea—Paclitaxel—kidney cancer	0.000477	0.000858	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Capecitabine—kidney cancer	0.000468	0.000842	CcSEcCtD
Dextroamphetamine—Dizziness—Paclitaxel—kidney cancer	0.000461	0.000829	CcSEcCtD
Dextroamphetamine—Urticaria—Capecitabine—kidney cancer	0.000454	0.000818	CcSEcCtD
Dextroamphetamine—Body temperature increased—Capecitabine—kidney cancer	0.000452	0.000814	CcSEcCtD
Dextroamphetamine—Abdominal pain—Capecitabine—kidney cancer	0.000452	0.000814	CcSEcCtD
Dextroamphetamine—Tension—Doxorubicin—kidney cancer	0.000443	0.000798	CcSEcCtD
Dextroamphetamine—Vomiting—Paclitaxel—kidney cancer	0.000443	0.000798	CcSEcCtD
Dextroamphetamine—Rash—Paclitaxel—kidney cancer	0.00044	0.000791	CcSEcCtD
Dextroamphetamine—Dermatitis—Paclitaxel—kidney cancer	0.000439	0.00079	CcSEcCtD
Dextroamphetamine—Nervousness—Doxorubicin—kidney cancer	0.000439	0.00079	CcSEcCtD
Dextroamphetamine—Headache—Paclitaxel—kidney cancer	0.000437	0.000786	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Capecitabine—kidney cancer	0.000421	0.000758	CcSEcCtD
Dextroamphetamine—Agitation—Doxorubicin—kidney cancer	0.000415	0.000747	CcSEcCtD
Dextroamphetamine—Nausea—Paclitaxel—kidney cancer	0.000414	0.000745	CcSEcCtD
Dextroamphetamine—Selegiline—ABCB1—kidney cancer	0.000413	0.0333	CrCbGaD
Dextroamphetamine—Asthenia—Capecitabine—kidney cancer	0.00041	0.000739	CcSEcCtD
Dextroamphetamine—Palpitations—Doxorubicin—kidney cancer	0.000399	0.000718	CcSEcCtD
Dextroamphetamine—Convulsion—Doxorubicin—kidney cancer	0.000391	0.000704	CcSEcCtD
Dextroamphetamine—Diarrhoea—Capecitabine—kidney cancer	0.000391	0.000704	CcSEcCtD
Dextroamphetamine—Hypertension—Doxorubicin—kidney cancer	0.00039	0.000702	CcSEcCtD
Dextroamphetamine—Chest pain—Doxorubicin—kidney cancer	0.000385	0.000692	CcSEcCtD
Dextroamphetamine—Anxiety—Doxorubicin—kidney cancer	0.000383	0.00069	CcSEcCtD
Dextroamphetamine—Dizziness—Capecitabine—kidney cancer	0.000378	0.000681	CcSEcCtD
Dextroamphetamine—Dry mouth—Doxorubicin—kidney cancer	0.000376	0.000677	CcSEcCtD
Dextroamphetamine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000369	0.000664	CcSEcCtD
Dextroamphetamine—Infection—Doxorubicin—kidney cancer	0.000366	0.000659	CcSEcCtD
Dextroamphetamine—Vomiting—Capecitabine—kidney cancer	0.000364	0.000655	CcSEcCtD
Dextroamphetamine—Rash—Capecitabine—kidney cancer	0.000361	0.000649	CcSEcCtD
Dextroamphetamine—Dermatitis—Capecitabine—kidney cancer	0.00036	0.000648	CcSEcCtD
Dextroamphetamine—Tachycardia—Doxorubicin—kidney cancer	0.00036	0.000648	CcSEcCtD
Dextroamphetamine—Headache—Capecitabine—kidney cancer	0.000358	0.000645	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Doxorubicin—kidney cancer	0.000357	0.000641	CcSEcCtD
Dextroamphetamine—Anorexia—Doxorubicin—kidney cancer	0.000352	0.000633	CcSEcCtD
Dextroamphetamine—Nausea—Capecitabine—kidney cancer	0.00034	0.000611	CcSEcCtD
Dextroamphetamine—Insomnia—Doxorubicin—kidney cancer	0.000334	0.0006	CcSEcCtD
Dextroamphetamine—Dyspnoea—Doxorubicin—kidney cancer	0.000329	0.000592	CcSEcCtD
Dextroamphetamine—Somnolence—Doxorubicin—kidney cancer	0.000328	0.00059	CcSEcCtD
Dextroamphetamine—Dyspepsia—Doxorubicin—kidney cancer	0.000325	0.000584	CcSEcCtD
Dextroamphetamine—Decreased appetite—Doxorubicin—kidney cancer	0.000321	0.000577	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000318	0.000573	CcSEcCtD
Dextroamphetamine—Fatigue—Doxorubicin—kidney cancer	0.000318	0.000572	CcSEcCtD
Dextroamphetamine—Constipation—Doxorubicin—kidney cancer	0.000315	0.000567	CcSEcCtD
Dextroamphetamine—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000302	0.000543	CcSEcCtD
Dextroamphetamine—Urticaria—Doxorubicin—kidney cancer	0.000293	0.000527	CcSEcCtD
Dextroamphetamine—Abdominal pain—Doxorubicin—kidney cancer	0.000292	0.000525	CcSEcCtD
Dextroamphetamine—Body temperature increased—Doxorubicin—kidney cancer	0.000292	0.000525	CcSEcCtD
Dextroamphetamine—Hypersensitivity—Doxorubicin—kidney cancer	0.000272	0.000489	CcSEcCtD
Dextroamphetamine—Asthenia—Doxorubicin—kidney cancer	0.000265	0.000476	CcSEcCtD
Dextroamphetamine—Diarrhoea—Doxorubicin—kidney cancer	0.000252	0.000454	CcSEcCtD
Dextroamphetamine—Dizziness—Doxorubicin—kidney cancer	0.000244	0.000439	CcSEcCtD
Dextroamphetamine—Vomiting—Doxorubicin—kidney cancer	0.000234	0.000422	CcSEcCtD
Dextroamphetamine—Rash—Doxorubicin—kidney cancer	0.000233	0.000418	CcSEcCtD
Dextroamphetamine—Dermatitis—Doxorubicin—kidney cancer	0.000232	0.000418	CcSEcCtD
Dextroamphetamine—Headache—Doxorubicin—kidney cancer	0.000231	0.000416	CcSEcCtD
Dextroamphetamine—Nausea—Doxorubicin—kidney cancer	0.000219	0.000394	CcSEcCtD
Dextroamphetamine—CYP2D6—Biological oxidations—PTGS1—kidney cancer	0.000124	0.00166	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FLT1—kidney cancer	0.000124	0.00166	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—RAF1—kidney cancer	0.000119	0.0016	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—POMC—kidney cancer	0.000117	0.00157	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—JUNB—kidney cancer	0.000115	0.00154	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PAK1—kidney cancer	0.000115	0.00154	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	0.000113	0.00152	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—PIK3CA—kidney cancer	0.000113	0.00152	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000112	0.00151	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—kidney cancer	0.000111	0.00149	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—OR4C13—kidney cancer	0.000109	0.00147	CbGpPWpGaD
Dextroamphetamine—ADRA1B—AMPK Signaling—TP53—kidney cancer	0.000109	0.00147	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—kidney cancer	0.000107	0.00144	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—ANXA1—kidney cancer	0.000107	0.00143	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—POMC—kidney cancer	0.000106	0.00142	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—kidney cancer	0.000106	0.00142	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—PIK3CA—kidney cancer	0.0001	0.00135	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.0001	0.00135	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—OR4C13—kidney cancer	9.7e-05	0.0013	CbGpPWpGaD
Dextroamphetamine—ADRA1A—AMPK Signaling—TP53—kidney cancer	9.69e-05	0.0013	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	9.67e-05	0.0013	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—ANXA1—kidney cancer	9.47e-05	0.00127	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF2—kidney cancer	9.38e-05	0.00126	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—PIK3CA—kidney cancer	9.37e-05	0.00126	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CDKN2B—kidney cancer	9.33e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—kidney cancer	9.29e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—LATS1—kidney cancer	9.29e-05	0.00125	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTP1—kidney cancer	9.17e-05	0.00123	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IGF1R—kidney cancer	9.06e-05	0.00122	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTP1—kidney cancer	9.04e-05	0.00121	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	8.87e-05	0.00119	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—RAF1—kidney cancer	8.73e-05	0.00117	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—IL2—kidney cancer	8.62e-05	0.00116	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	8.57e-05	0.00115	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—BRAF—kidney cancer	8.52e-05	0.00115	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—AKAP13—kidney cancer	8.45e-05	0.00114	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—GSTM1—kidney cancer	8.42e-05	0.00113	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—GSTM1—kidney cancer	8.31e-05	0.00112	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—LATS1—kidney cancer	8.25e-05	0.00111	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—MAPK1—kidney cancer	8.19e-05	0.0011	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP1A1—kidney cancer	7.98e-05	0.00107	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AMER1—kidney cancer	7.9e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP1A1—kidney cancer	7.88e-05	0.00106	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—IL2—kidney cancer	7.83e-05	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—AKAP13—kidney cancer	7.68e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	7.64e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	7.63e-05	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—AKAP13—kidney cancer	7.51e-05	0.00101	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—HIF1A—kidney cancer	7.46e-05	0.001	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TSC2—kidney cancer	7.44e-05	0.001	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ITPR2—kidney cancer	7.19e-05	0.000966	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KDR—kidney cancer	7.14e-05	0.000959	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—RAF1—kidney cancer	7.12e-05	0.000956	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ACY1—kidney cancer	7.02e-05	0.000944	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AMER1—kidney cancer	7.01e-05	0.000942	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	6.86e-05	0.000921	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—AKAP13—kidney cancer	6.82e-05	0.000916	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	6.78e-05	0.000911	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	6.76e-05	0.000909	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GPC3—kidney cancer	6.62e-05	0.000889	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CER1—kidney cancer	6.62e-05	0.000889	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—APC—kidney cancer	6.57e-05	0.000883	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KIT—kidney cancer	6.57e-05	0.000883	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ITPR2—kidney cancer	6.53e-05	0.000877	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—kidney cancer	6.42e-05	0.000862	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ITPR2—kidney cancer	6.38e-05	0.000858	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—kidney cancer	6.37e-05	0.000856	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—MAPK3—kidney cancer	6.3e-05	0.000846	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—POMC—kidney cancer	6.26e-05	0.000841	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—BRAF—kidney cancer	6.18e-05	0.00083	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	6.09e-05	0.000818	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—ANXA1—kidney cancer	6.02e-05	0.000809	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—MAPK1—kidney cancer	5.99e-05	0.000805	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PDHB—kidney cancer	5.97e-05	0.000802	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—POMC—kidney cancer	5.95e-05	0.0008	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CER1—kidney cancer	5.88e-05	0.00079	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GPC3—kidney cancer	5.88e-05	0.00079	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ITPR2—kidney cancer	5.8e-05	0.000779	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—PIK3CA—kidney cancer	5.72e-05	0.000769	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—KRAS—kidney cancer	5.66e-05	0.00076	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—SFRP2—kidney cancer	5.63e-05	0.000756	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CCBL1—kidney cancer	5.62e-05	0.000754	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	5.5e-05	0.000739	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—ANXA1—kidney cancer	5.47e-05	0.000735	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—ANXA1—kidney cancer	5.35e-05	0.000719	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	5.24e-05	0.000704	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—POMC—kidney cancer	5.22e-05	0.000702	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—PIK3CA—kidney cancer	5.2e-05	0.000698	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RAF1—kidney cancer	5.16e-05	0.000693	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—RELA—kidney cancer	5.14e-05	0.00069	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—ERBB2—kidney cancer	5.1e-05	0.000686	CbGpPWpGaD
Dextroamphetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—kidney cancer	5.08e-05	0.000683	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MTOR—kidney cancer	5.04e-05	0.000677	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—SFRP2—kidney cancer	5e-05	0.000671	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	4.95e-05	0.000665	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	4.89e-05	0.000657	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—MAPK1—kidney cancer	4.88e-05	0.000656	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GLIPR1—kidney cancer	4.87e-05	0.000654	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PPAT—kidney cancer	4.87e-05	0.000654	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—ANXA1—kidney cancer	4.86e-05	0.000653	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CDKN1B—kidney cancer	4.73e-05	0.000635	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	4.65e-05	0.000625	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—POMC—kidney cancer	4.64e-05	0.000623	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—IL2—kidney cancer	4.63e-05	0.000622	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	4.54e-05	0.00061	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CASP2—kidney cancer	4.53e-05	0.000609	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKAP13—kidney cancer	4.53e-05	0.000609	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—FH—kidney cancer	4.53e-05	0.000608	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—APRT—kidney cancer	4.53e-05	0.000608	CbGpPWpGaD
Dextroamphetamine—ADRA1A—G alpha (q) signalling events—PIK3CA—kidney cancer	4.51e-05	0.000606	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CCND1—kidney cancer	4.51e-05	0.000606	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—JUN—kidney cancer	4.5e-05	0.000605	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—CTNNB1—kidney cancer	4.47e-05	0.0006	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	4.39e-05	0.00059	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PTEN—kidney cancer	4.35e-05	0.000585	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—kidney cancer	4.32e-05	0.00058	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GPC3—kidney cancer	4.26e-05	0.000572	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—GRB7—kidney cancer	4.15e-05	0.000557	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CA2—kidney cancer	4.14e-05	0.000556	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	4.04e-05	0.000542	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALAD—kidney cancer	4.03e-05	0.000542	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CASP2—kidney cancer	4.03e-05	0.000541	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKAP13—kidney cancer	4.03e-05	0.000541	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ST3GAL2—kidney cancer	3.94e-05	0.000529	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—VEGFA—kidney cancer	3.93e-05	0.000528	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ITPR2—kidney cancer	3.86e-05	0.000518	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ALDH1A1—kidney cancer	3.85e-05	0.000517	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—kidney cancer	3.83e-05	0.000514	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK3—kidney cancer	3.72e-05	0.0005	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PGK1—kidney cancer	3.69e-05	0.000496	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC5A3—kidney cancer	3.69e-05	0.000496	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—GRB7—kidney cancer	3.68e-05	0.000495	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—LDHB—kidney cancer	3.62e-05	0.000486	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MYC—kidney cancer	3.62e-05	0.000486	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—MAPK1—kidney cancer	3.54e-05	0.000475	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CTNNA1—kidney cancer	3.5e-05	0.00047	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—EIF4EBP1—kidney cancer	3.48e-05	0.000467	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HSPB1—kidney cancer	3.48e-05	0.000467	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ITPR2—kidney cancer	3.42e-05	0.00046	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—KRAS—kidney cancer	3.34e-05	0.000449	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PSMD7—kidney cancer	3.23e-05	0.000434	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSC1—kidney cancer	3.23e-05	0.000434	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ANXA1—kidney cancer	3.23e-05	0.000434	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CA9—kidney cancer	3.14e-05	0.000421	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FLT1—kidney cancer	3.13e-05	0.00042	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CTNNA1—kidney cancer	3.11e-05	0.000417	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—EIF4EBP1—kidney cancer	3.09e-05	0.000415	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HSPB1—kidney cancer	3.09e-05	0.000415	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—PIK3CA—kidney cancer	3.07e-05	0.000413	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TP53—kidney cancer	2.97e-05	0.000399	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—POMC—kidney cancer	2.95e-05	0.000396	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JUNB—kidney cancer	2.9e-05	0.00039	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PAK1—kidney cancer	2.9e-05	0.00039	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PSMD7—kidney cancer	2.87e-05	0.000386	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSC1—kidney cancer	2.87e-05	0.000386	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ANXA1—kidney cancer	2.87e-05	0.000386	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FLT1—kidney cancer	2.78e-05	0.000373	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—POMC—kidney cancer	2.68e-05	0.00036	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CRABP1—kidney cancer	2.67e-05	0.000358	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—POMC—kidney cancer	2.62e-05	0.000352	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PAK1—kidney cancer	2.58e-05	0.000346	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JUNB—kidney cancer	2.58e-05	0.000346	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ITPR2—kidney cancer	2.48e-05	0.000333	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—POMC—kidney cancer	2.38e-05	0.00032	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF2—kidney cancer	2.37e-05	0.000319	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN2B—kidney cancer	2.36e-05	0.000317	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IGF1R—kidney cancer	2.29e-05	0.000308	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTT1—kidney cancer	2.26e-05	0.000304	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ACHE—kidney cancer	2.26e-05	0.000304	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—RAF1—kidney cancer	2.21e-05	0.000297	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—IL2—kidney cancer	2.18e-05	0.000293	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SCARB1—kidney cancer	2.14e-05	0.000288	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS1—kidney cancer	2.12e-05	0.000285	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF2—kidney cancer	2.11e-05	0.000283	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN2B—kidney cancer	2.1e-05	0.000282	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PSMD7—kidney cancer	2.08e-05	0.000279	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IGF1R—kidney cancer	2.04e-05	0.000274	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—IL2—kidney cancer	1.98e-05	0.000266	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—BCHE—kidney cancer	1.97e-05	0.000265	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—RAF1—kidney cancer	1.96e-05	0.000264	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC5A5—kidney cancer	1.95e-05	0.000261	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—IL2—kidney cancer	1.94e-05	0.00026	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—HIF1A—kidney cancer	1.89e-05	0.000254	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TSC2—kidney cancer	1.88e-05	0.000253	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—SLC2A1—kidney cancer	1.88e-05	0.000252	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KDR—kidney cancer	1.81e-05	0.000243	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—IL2—kidney cancer	1.76e-05	0.000236	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—HIF1A—kidney cancer	1.68e-05	0.000225	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TSC2—kidney cancer	1.67e-05	0.000225	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—APC—kidney cancer	1.66e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KIT—kidney cancer	1.66e-05	0.000223	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KDR—kidney cancer	1.6e-05	0.000215	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	1.59e-05	0.000214	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—POMC—kidney cancer	1.58e-05	0.000213	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTP1—kidney cancer	1.57e-05	0.000211	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—BRAF—kidney cancer	1.56e-05	0.00021	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	1.52e-05	0.000204	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—ABCB1—kidney cancer	1.48e-05	0.000199	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KIT—kidney cancer	1.48e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—APC—kidney cancer	1.48e-05	0.000198	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	1.45e-05	0.000195	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—GSTM1—kidney cancer	1.44e-05	0.000194	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	1.43e-05	0.000192	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAPK3—kidney cancer	1.41e-05	0.00019	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—POMC—kidney cancer	1.41e-05	0.000189	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—BRAF—kidney cancer	1.39e-05	0.000187	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP1A1—kidney cancer	1.37e-05	0.000183	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—MAPK1—kidney cancer	1.35e-05	0.000181	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	1.32e-05	0.000177	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RAF1—kidney cancer	1.31e-05	0.000175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—RELA—kidney cancer	1.3e-05	0.000175	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	1.29e-05	0.000173	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—PIK3CA—kidney cancer	1.29e-05	0.000173	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MTOR—kidney cancer	1.27e-05	0.000171	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—KRAS—kidney cancer	1.27e-05	0.000171	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	1.2e-05	0.000161	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—IL2—kidney cancer	1.17e-05	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—PIK3CA—kidney cancer	1.17e-05	0.000157	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RAF1—kidney cancer	1.16e-05	0.000156	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—RELA—kidney cancer	1.15e-05	0.000155	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—ERBB2—kidney cancer	1.15e-05	0.000154	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CCND1—kidney cancer	1.14e-05	0.000153	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—JUN—kidney cancer	1.14e-05	0.000153	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MTOR—kidney cancer	1.13e-05	0.000152	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	1.13e-05	0.000152	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PTEN—kidney cancer	1.1e-05	0.000148	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CDKN1B—kidney cancer	1.06e-05	0.000143	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—IL2—kidney cancer	1.04e-05	0.00014	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—POMC—kidney cancer	1.02e-05	0.000137	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CCND1—kidney cancer	1.01e-05	0.000136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—JUN—kidney cancer	1.01e-05	0.000136	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—CTNNB1—kidney cancer	1e-05	0.000135	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	9.95e-06	0.000134	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PTEN—kidney cancer	9.78e-06	0.000131	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	9.41e-06	0.000126	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MYC—kidney cancer	9.15e-06	0.000123	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	8.95e-06	0.00012	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—VEGFA—kidney cancer	8.83e-06	0.000119	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—KRAS—kidney cancer	8.46e-06	0.000114	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK3—kidney cancer	8.36e-06	0.000112	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MYC—kidney cancer	8.13e-06	0.000109	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTGS2—kidney cancer	8.12e-06	0.000109	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—MAPK1—kidney cancer	7.95e-06	0.000107	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	7.77e-06	0.000104	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TP53—kidney cancer	7.52e-06	0.000101	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—KRAS—kidney cancer	7.51e-06	0.000101	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PTEN—kidney cancer	7.08e-06	9.51e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—PIK3CA—kidney cancer	6.9e-06	9.27e-05	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TP53—kidney cancer	6.68e-06	8.97e-05	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—PIK3CA—kidney cancer	5e-06	6.71e-05	CbGpPWpGaD
